Clinical Trial Update: Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole [Phase 3]

View source ↗

Summary

Phase 3 trial results for ocriplasmin in symptomatic vitreomacular adhesion including macular hole have been completed and results posted in January 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Hole
• Vitreomacular Adhesion

Drugs mentioned

• Jetrea (ocriplasmin)

Snippet

Sponsor: ThromboGenics | Conditions: Vitreomacular Adhesion Including Macular Hole | Phase 3 | Status: COMPLETED | Results posted: 2016-01-11